secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001564590-21-043064
Event type: earnings
Sentiment:  positive
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q2 total revenue $11.9M (+180%), core lung diagnostics $4.8M (+109%); NGS test launch accelerated to Q1 2022
--------------------------------------------------------------------------------

- Total revenue $11.9M (+180% YoY); core lung diagnostic revenue $4.8M (+109%).
- COVID-19 testing revenue $6.1M (+345%) but declining sequentially; net loss $11.4M (+38%).
- Gross profit $4.8M (40% margin); operating expenses $15.4M (+93%) due to sales force buildout.
- Nodify XL2 milestone triggers $37M obligation payable over six quarterly installments starting Jan 2022.
- Accelerated launch of 72-hour liquid NGS test to Q1 2022; cash $56.3M; expects $3.1M PPP loan forgiveness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000156459021043064/0001564590-21-043064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000156459021043064/bdsx-8k_20210810.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-043064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer